Citigroup Maintains Neutral on Carrier Global, Raises Price Target to $45

Citigroup analyst Vladimir Bystricky maintains Carrier Global (NYSE:CARR) with a Neutral and raises the price target from $39 to $45.

byBenzinga Newsdesk

December 9, 2022

1 minute read

Citigroup analyst Vladimir Bystricky maintains Carrier Global (NYSE:CARR) with a Neutral and raises the price target from $39 to $45.

Wolfe Research Initiates Coverage On PTC with Outperform Rating, Announces Price Target of $155

By Benzinga Newsdesk

August 17, 4:39 AM

Wolfe Research analyst Gal Munda initiates coverage on PTC (NASDAQ:PTC) with a Outperform rating and announces Price Target of $155.

PTC

Revolve Group Q4 EPS $0.39 Beats $0.18 Estimate, Sales $239.81M Beat $220.93M Estimate

By Bill Haddad

February 23, 5:45 PM

Revolve Group (NYSE:RVLV) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.18 by 116.67 percent. This is a 50 percent increase over earnings of $0.26 per share from the same

RVLV

Meta Platforms, Herbalife And Some Other Big Stocks Moving Lower On Tuesday

By Lisa Levin

December 6, 12:31 PM

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Tuesday. Here are some big stocks recording losses in today’s session.

APP

News

VBI Vaccines Announces PreHevbrio Is Now Available In The United States For The Prevention Of Hepatitis B In Adults

By Bill Haddad

March 29, 8:14 AM

- PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] is the only approved 3-antigen hepatitis B vaccine for adults in the U.S. - FDA approval of PreHevbrio received in November 2021 - PreHevbrio added to ACIP list

VBIV

Citigroup Maintains Neutral on Carrier Global, Raises Price Target to $45

Related Posts

Wolfe Research Initiates Coverage On PTC with Outperform Rating, Announces Price Target of $155

Revolve Group Q4 EPS $0.39 Beats $0.18 Estimate, Sales $239.81M Beat $220.93M Estimate

Meta Platforms, Herbalife And Some Other Big Stocks Moving Lower On Tuesday

VBI Vaccines Announces PreHevbrio Is Now Available In The United States For The Prevention Of Hepatitis B In Adults